ZCM
STLN

Zebra Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Zebra Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,484
Closed -$127K – 87
2022
Q3 		$127K Buy
+27,484
New +$162K 0.48% 65

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Zebra Capital Management's STLN Position: Q4 2022 in Review

Zebra Capital Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2022, closing a stake of 27,484 shares — an estimated $127K sold.

Zebra Capital Management first reported a position in STLN in Q3 2022 and held it in 1 quarter. The position peaked at $127K in Q3 2022. 41 funds tracked by Wall St. Rank hold STLN as of Q4 2022.

  • Zebra Capital Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Zebra Capital Management sold 27,484 Starling Oncology Institute, Inc. Common Stock shares in Q4 2022, an estimated $127K.
  • Zebra Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Zebra Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $127K in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2022.

Based on Zebra Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.